Effectiveness of individualized management using WILFACTIN® in patients with von Willebrand disease during surgical procedures: A single-center study

Thromb Res. 2022 Dec:220:88-90. doi: 10.1016/j.thromres.2022.09.028. Epub 2022 Oct 11.

Authors

Lucia Rugeri¹, Rémi Benoit², Stéphanie Desage³, Yesim Dargaud³

Affiliations

¹ Unité Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France. Electronic address: lucia.rugeri@chu-lyon.fr.
² Service d'Hématologie Biologique, CHRU de Nancy, France.
³ Unité Hémostase Clinique, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.

PMID: 36274392
DOI: 10.1016/j.thromres.2022.09.028

No abstract available

Publication types

Letter

MeSH terms

Factor VIII
Humans
von Willebrand Diseases* / complications
von Willebrand Diseases* / drug therapy
von Willebrand Diseases* / surgery
von Willebrand Factor / therapeutic use

Substances

von Willebrand Factor
Factor VIII